The Patent Finder

PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates

ADC GmbH

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 11,690,918PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates
In force
 · High confidence
ADC Therapeutics S.A.In force
High confidence
US 10,722,594PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates
In force
 · High confidence
ADC Therapeutics S.A.In force
High confidence
US 9,919,056PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates
Lapsed Mar 20, 2026 on the fee record
Ended Mar 20, 2026 · High confidence
ADC Therapeutics S.A.Lapsed Mar 20, 2026 on the fee recordEnded Mar 20, 2026
High confidence
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by ADC GmbH.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited